NCT01658462 2026-03-16
VAROCE
Centre Oscar Lambret
Phase 2 Completed
Clinical Trials
67 trialsNCT03377023 2026-01-22
Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Active not recruiting
NCT02856425 2026-01-20
PEMBIB
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1 Completed
NCT03513484 2025-10-21
Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia
Northwestern University
Phase 1 Active not recruiting
NCT02863055 2025-09-19
NEMO
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Terminated
NCT02730416 2025-07-29
Combination Chemotherapy With Nintedanib / Placebo in Endometrial Cancer
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Phase 2 Completed
NCT02299141 2025-06-24
Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer
Washington University School of Medicine
Phase 2 Completed
NCT02496585 2025-04-16
Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01314105 2025-02-13
BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer
Boehringer Ingelheim
Phase 1 Completed
NCT02231164 2025-02-13
LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research
Boehringer Ingelheim
Phase 3 Terminated
NCT01346540 2025-02-12
A Phase I/II Study of Continuous Oral Treatment With BIBF 1120 Added to Standard Gemcitabine/Cisplatin Therapy in First Line NSCLC Patients With Squamous Cell Histology.
Boehringer Ingelheim
Phase 1 Completed
NCT02300298 2025-02-11
Nintedanib Plus Docetaxel in Japanese Patients With Adenocarcinoma Subtype Non-small Cell Lung Cancer After Failure of First Line Chemotherapy
Boehringer Ingelheim
Phase 1 Completed
NCT06071013 2025-01-23
Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients
China Medical University Hospital
Phase 1/2 Recruiting
NCT02182219 2025-01-22
Oral Treatment With BIBF 1120 Together With Docetaxel and Prednisone in Patients With Hormone Refractory Prostate Cancer
Boehringer Ingelheim
Phase 1 Completed
NCT02009579 2024-08-07
ENGOT-cx1/BGOG-cx1: 3 Weekly Carboplatin/Paclitaxel With or Without Nintedanib in Cervix Cancer
Belgian Gynaecological Oncology Group
Phase 2 Completed
NCT02225405 2024-05-08
Cisplatin, Docetaxel, and Nintedanib Before Surgery in Treating Patients With Previously Untreated Stage IB-IIIA Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT03287947 2022-08-09
LCI-GI-APX-NIN-001: Nintedanib in Metastatic Appendiceal Carcinoma
Wake Forest University Health Sciences
Phase 2 Terminated
NCT02665143 2022-04-08
A Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia
Yale University
Phase 2 Completed
NCT03292250 2022-03-29
Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]
Seoul National University Hospital
Phase 2 Completed
NCT01485874 2022-02-15
Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer
Hoosier Cancer Research Network
Phase 1 Terminated
NCT02568449 2021-12-09
Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT02808247 2021-09-20
ANITA
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Terminated
NCT02531737 2021-08-10
REFRACT
University Hospital, Limoges
Phase 2 Completed
NCT02393755 2021-07-08
Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer
Roswell Park Cancer Institute
Phase 1/2 Completed
NCT02668393 2021-01-29
Nintedanib and Weekly Docetaxel in Lung Adenocarcinoma
Boehringer Ingelheim
Phase 1 Completed
NCT02234596 2021-01-25
Nintedanib in Patients With Advanced Esophagogastric Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02308553 2020-10-14
NIPAWILMA
University Hospital, Essen
Phase 1/2 Completed
NCT01788982 2020-07-31
Nintedanib(BIBF1120) in Thyroid Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT02452463 2020-04-06
Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation Therapy
Roswell Park Cancer Institute
Phase 2 Terminated
NCT01362361 2019-09-19
AIO-KRK-0111
Martin-Luther-Universität Halle-Wittenberg
Phase 2 Completed
NCT02619162 2019-07-23
Nintedanib+Letrozole in Postmenopausal Women With Breast Cancer: Clinical Trial Safety and Pharmacodynamics
Centro Nacional de Investigaciones Oncologicas CARLOS III
Phase 1 Completed
NCT02389764 2019-07-17
Nintedanib For HER2-Negative Metastatic Inflammatory Breast Cancer (MIBC)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01610869 2019-05-29
METRO-BIBF
University College, London
Phase 2 Completed
NCT01907100 2019-03-18
Nintedanib (BIBF 1120) in Mesothelioma
Boehringer Ingelheim
Phase 2/3 Terminated
NCT02751385 2019-03-14
Investigation of the Effect of Nintedanib on the Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Patients With Non-small Cell Lung Cancer
Boehringer Ingelheim
Phase 1 Terminated
NCT00805194 2018-12-05
LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer
Boehringer Ingelheim
Phase 3 Completed
NCT01669798 2018-10-16
BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer
Duke University
Phase 2 Completed
NCT01022853 2018-07-30
Combination of BI6727 (Volasertib) and BIBF1120 in Solid Tumors
Boehringer Ingelheim
Phase 1 Completed
NCT02835833 2018-07-10
Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors
University of Alabama at Birmingham
Phase 1 Completed
NCT00801294 2017-12-29
A Phase II Trial of Weekly Alternating Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Advanced Colorectal Cancer
Boehringer Ingelheim
Phase 2 Completed
NCT02182063 2017-12-28
A Study With BIBF 1120 in Patients With Hormone Refractory Prostate Cancer
Boehringer Ingelheim
Phase 2 Completed
NCT01015118 2017-12-07
LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer
Boehringer Ingelheim
Phase 3 Completed
NCT01004003 2017-10-26
Phase I/II Comparison of Efficacy and Safety of BIBF 1120 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Boehringer Ingelheim
Phase 2 Completed
NCT01225887 2017-10-09
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
GOG Foundation
Phase 2 Completed
NCT01441297 2017-08-25
BIBF 1120 as Second Line Treatment for Small Cell Lung Cancer
National Cancer Center, Korea
Phase 2 Completed
NCT02149108 2017-07-21
Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)
Boehringer Ingelheim
Phase 3 Completed
NCT01948141 2017-06-08
Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens
Roswell Park Cancer Institute
Phase 2 Completed
NCT02856867 2017-05-09
MEGAN
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Withdrawn
NCT00806819 2017-02-02
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC
Boehringer Ingelheim
Phase 3 Completed
NCT00710762 2016-08-15
A Randomised Placebo-Controlled Phase II Study of Continuous Maintenance Treatment With BIBF 1120 Following Chemotherapy in Patients With Relapsed Ovarian Cancer
Boehringer Ingelheim
Phase 2 Completed